The public should be guided by the messages of the U.S. Surgeon General, the Food and Drug Administration (FDA) and other public health authorities worldwide in making decisions concerning the use of tobacco products.

Our tobacco companies' efforts to communicate about health risks begin with ongoing compliance with federal laws and regulations requiring health warnings on tobacco products.

Congressionally-mandated health warnings have been on cigarette packs since 1966 and cigarette brand advertising since 1972. Similar warning requirements have been in place since 1986 for smokeless tobacco products and since 2000 for the cigars John Middleton sells. Our tobacco companies provide reports, such as ingredient disclosures and information about harmful or potentially harmful constituents in tobacco products to various federal and state agencies, including the FDA.

For more information about product ingredients and how our tobacco companies communicate about the health effects of their products, visit PM USA's, USSTC's and John Middleton's corporate websites.

Seeking Authorization to Communicate Reduced Harm Information

We can only compete in the marketplace with products authorized by the FDA. And we can only communicate reduced harm information if the FDA permits.

That's why we are seeking authorization from the FDA to put truthful, accurate information about reduced-risk products in the hands of consumers so that they can make a choice that's right for them. To date, we have:

 

  • Supported Philip Morris International (PMI) on its Modified Risk Tobacco Product application (MRTPA) application for IQOS tobacco heating system. Philip Morris USA has an exclusive agreement with PMI to commercialize IQOS in the United States. On July 7, 2020, FDA authorized the marketing of the IQOS as a modified risk tobacco product with a reduced exposure claim.
  • Submitted MRTPA for Copenhagen Snuff.

 

We believe it is critically important that the FDA take steps to foster the innovation of potentially reduced risk products. For tobacco harm reduction to be successful, a marketplace of FDA-authorized reduced-risk products must be in place, with more information about the relative risks of those products being communicated to adult smokers. The regulatory system should respect the rights of adults to make decisions based on accurate information. To make this a reality, the FDA needs to establish clear foundational rules for bringing these new innovative products to market.